US Drug Discovery Shifting to China

Posted 5/7/25

America’s leadership in drug innovation is eroding as pharmaceutical companies increasingly source new compounds from China, former FDA Commissioner Scott Gottlieb warns in STAT. In 2024, one-third of all new drugs licensed by U.S. firms originated in Chinese labs — a stark contrast to five years ago, when that number was zero.

This item is available in full to subscribers.

Please log in to continue

Log in